Amid the global biopharmaceutical paradigm shift from "target discovery" to "precision delivery," METIS TECHBIO-P (07666) is leveraging its proprietary Biological AI infrastructure, the NanoForge platform, to deepen its leadership in the AI for Science sector and unlock core innovation value. According to reports, on August 25, the company disclosed its 2026 interim results. During the reporting period, revenue reached RMB 154 million, a year-on-year surge of 13,339%, exceeding the full-year 2025 revenue by 47%.
Simultaneously, the company's financial structure continued to optimize: R&D expenses grew 48.1% year-on-year to RMB 172 million; adjusted net loss narrowed significantly by 56.4% to RMB 51.1 million; cash reserves stood at RMB 3.025 billion, while the debt-to-asset ratio improved from 19.3% at the end of 2025 to 9%. These accelerating core financial metrics not only confirm that the AI for Science sector has reached a pivotal inflection point for scalable validation but also underscore the substantial growth potential of METIS TECHBIO's primary business. As NanoForge's commercialization outcomes enter a phase of concentrated release, the company's core innovation value is poised to gain sustained recognition from both global industry players and capital markets.
Commercialization Milestones Accelerate, Industrial Ecosystem Empowerment Advances
In the first half of 2026, NanoForge's platform capabilities received substantive endorsement from international professional investment institutions and leading multinational pharmaceutical companies, with consecutive commercial milestones validating its ability to consistently generate globally valuable innovative assets. On June 30, METIS TECHBIO announced an exclusive global licensing agreement with Boulevard Bio, supported by Deerfield, a premier global health investment and innovation platform, with a total value of up to USD 1.6 billion—setting a new record for the largest single preclinical TCE licensing deal in China.
During the reporting period, METIS TECHBIO also achieved infrastructure-level external application of NanoForge, advancing its AiTEM AI-driven formulation innovation platform through a collaboration with Hengrui Medicine. Additionally, the company signed an exclusive licensing agreement with BioThunder AG, securing RMB 15 million in exclusivity fees covering up to 10 candidate products, and entered a strategic partnership with Apeloa Pharmaceutical to jointly build an "AI+CDMO" pharmaceutical innovation ecosystem. Beyond these, the company has continuously empowered global CGT sector partners through NanoForge, establishing technical collaborations with multiple benchmark enterprises across cell therapy, gene therapy, fibrotic cell programming, and in vivo immunotherapy. These collaborations span scientific research partnerships, joint development, and delivery technology licensing, with a potential aggregate transaction value exceeding RMB 6 billion.
Over 10 Pipeline Candidates in Tiered Layout, Three-Dimensional Capability Leap
On the R&D front, METIS TECHBIO's total R&D expenditure reached RMB 172 million during the reporting period. Supported by robust investment and NanoForge's full-stack capabilities across AiLNP, AiRNA, AiProtein, and AiTEM, the company has established a pipeline of over 10 candidates covering oncology, immunology, metabolic disorders, and central nervous system diseases. This includes a tiered layout of small molecule formulations, mRNA-encoded TCEs/NKCEs, mRNA therapeutic vaccines, and protein/antibody modalities.
Take MTS-128, the asset in the landmark BD deal with Deerfield, as an example. This next-generation trispecific TCE was self-developed through NanoForge's AI-driven molecular engineering. Unlike traditional antibody development, MTS-128 achieves end-to-end R&D from molecular design to optimization, showcasing METIS TECHBIO's deep integration of AI with protein drug design and further validating NanoForge's capacity to continuously produce innovative assets. Recently, the world's first clinically validated mRNA therapeutic cancer vaccine confirmed the feasibility and commercial value of mRNA technology in oncology. In this context, NanoForge's mRNA tumor vaccine R&D capabilities and LNP delivery "picks-and-shovels" positioning gained secondary market recognition, driving the company's share price up more than 35% in a single day.
The underlying driver behind METIS TECHBIO's concentrated delivery of commercialization results and technological breakthroughs lies in NanoForge's capability leap in life sciences. During the reporting period, the company continued to refine NanoForge's end-to-end Biological AI capabilities, advancing the scaling laws of Biological AI across three dimensions: Design Space, Delivery, and Modality. The core value extends beyond improving efficiency in existing R&D processes to continuously expanding the computable and engineerable design space within life sciences. In short, METIS TECHBIO is leveraging NanoForge to establish an innovative paradigm of "AI-designed small molecules—AI-designed macromolecules and biological functions—AI understanding and regulation of cellular states," reshaping the foundational logic of the cell reprogramming era.
As Lai Caida, Chairman and CEO of METIS TECHBIO, stated: "We aim to use AI to elevate drug development from project-by-project trial-and-error to a life engineering system capable of continuous learning, repeated validation, and scalable output. Moving from drug delivery to programming life represents the most critical strategic leap for METIS TECHBIO in the next phase."